Table 2.

Prevalence and risk factors for PE-related unfavorable outcome in patients with pulmonary embolism

Risk factor	Unfavorable outcome (n=25, 17.7%)	Univariatea	Multivariateb
		P-value	P-value	95% CI
Age (y)	71.0±12.5	0.304	0.338	0.267–4.058
<50	1 (4.0)
51–69	9 (36.0)
≥70	15 (60.0)
Male	11 (44.0)	0.816	0.352	0.513–6.524
Location of PE		0.734	0.993	0.303–3.265
Main & lobar arteries	16 (64.0)
Segmental & subsegmental arteries	9 (36.0)
PE-related symptoms	15 (60.0)	0.847	0.586	0.198–2.499
DVT	14 (56.0)	0.240	0.318	0.594–4.961
Proximal	10 (40.0)
Immobilization ≥3 days	13 (52.0)	0.331	0.860	0.261–3.069
History of surgery or trauma ≤4 weeks	5 (20.0)	0.429	0.827	0.256–5.489
Active malignancy and/or chemotherapy	7 (28.0)	0.967	0.995	0.295–3.410
Comorbidities
HTN	14 (56.0)	0.935	0.429	0.181–2.067
DM	8 (32.0)	0.925	0.915	0.307–3.739
CAD	2 (8.0)	1.000	0.795	0.147–12.200
Congestive heart failure	3 (12.0)	0.446	0.987	0.155–6.667
Cerebrovascular disease	6 (24.0)	0.714	0.647	0.161–3.113
Underlying pulmonary disease	10 (40.0)	0.721	0.597	0.211–2.443
Smoking	2 (8.0)	1.000	0.623	0.239–10.947
HR >100/min	17 (68.0)	0.001	0.009	1.521–17.713
RR >30/min	5 (20.0)	0.009	0.176	0.544–28.150
SpO2 <90%	14 (56.0)	0.001	0.038	1.072–11.513
Anticoagulation treatment	19 (76.0)	0.089	0.169	0.077–1.569

Values are presented as mean±standard deviation or number (%).

PE, pulmonary embolism; CI, confidence interval; DVT, deep venous thrombosis; HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; HR, heart rate; RR, respiratory rate; SpO₂, peripheral oxygen saturation.

^aChi-square test or Fisher’s exact test,

^blogistic regression model.